W F Huffman
Overview
Explore the profile of W F Huffman including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
47
Citations
183
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Seefeld M, Miller W, Newlander K, BURGESS W, Payne D, Rittenhouse S, et al.
Bioorg Med Chem Lett
. 2001 Aug;
11(17):2241-4.
PMID: 11527706
An SAR study of a screening lead has led to the identification of 2,9-disubstituted 1,2,3,4-tetrahydropyrido[3,4-b]indoles as inhibitors of Staphylococcus aureus enoyl acyl carrier protein reductase (FabI).
2.
Heerding D, Chan G, DeWolf W, Fosberry A, Janson C, Jaworski D, et al.
Bioorg Med Chem Lett
. 2001 Aug;
11(16):2061-5.
PMID: 11514139
1,4-Disubstituted imidazole inhibitors of Staphylococcus aureus and Escherichia coli enoyl acyl carrier protein reductase (FabI) have been identified. Crystal structure data shows the inhibitor 1 bound in the enzyme active...
3.
Lark M, Stroup G, Dodds R, Kapadia R, Hoffman S, Hwang S, et al.
J Bone Miner Res
. 2001 Feb;
16(2):319-27.
PMID: 11204432
An orally active, nonpeptide Arg-Gly-Asp (RGD) mimetic alpha(v)beta3 antagonist, (S)-3-Oxo-8-[2-[6-(methylamino)-pyridin-2-yl]-1-ethoxy]-2-(2,2,2-trifluoroethyl)-2,3,4,5-tetrahydro-1H-2-benzazepine-4-acetic acid (compound 1), has been generated, which prevented net bone loss and inhibited cancellous bone turnover in vivo. The compound...
4.
Heerding D, Abruzzese M, Alberts D, Burgess J, Callahan J, Huffman W, et al.
Bioorg Med Chem Lett
. 2000 Mar;
10(6):531-4.
PMID: 10741547
The activity of a novel series of peptidomimetic hematoregulatory compounds, designed based on a pharmacophore model inferred from the structure activity relationships of a peptide SK&F 107647 (1), is reported....
5.
Miller W, Alberts D, Bhatnagar P, Bondinell W, Callahan J, Calvo R, et al.
J Med Chem
. 2000 Jan;
43(1):22-6.
PMID: 10633035
No abstract available.
6.
Ward K, Azzarano L, Bondinell W, Cousins R, Huffman W, Jakas D, et al.
Drug Metab Dispos
. 1999 Oct;
27(11):1232-41.
PMID: 10534306
Allometric scaling may be used in drug development to predict the pharmacokinetics of xenobiotics in humans from animal data. Although allometry may be successful for compounds that are excreted unchanged...
7.
Lark M, Stroup G, Hwang S, James I, Rieman D, Drake F, et al.
J Pharmacol Exp Ther
. 1999 Oct;
291(2):612-7.
PMID: 10525079
The Arg-Gly-Asp (RGD)-binding integrin alpha(V)beta(3) is highly expressed on osteoclasts and has been proposed to mediate cell-matrix adhesion required for osteoclast-mediated bone resorption. Antagonism of this receptor should prevent stable...
8.
Miller W, Bondinell W, Cousins R, Erhard K, Jakas D, Keenan R, et al.
Bioorg Med Chem Lett
. 1999 Jul;
9(13):1807-12.
PMID: 10406646
A new series of potent nonpeptide vitronectin receptor antagonists, based on a novel carbocyclic Gly-Asp mimetic, has been discovered. A representative of this series, SB 265123 (4), has 100% oral...
9.
Keenan R, Callahan J, Samanen J, Bondinell W, Calvo R, Chen L, et al.
J Med Chem
. 1999 Mar;
42(4):545-59.
PMID: 10052962
Previously, we reported the direct design of highly potent nonpeptide 3-oxo-1,4-benzodiazepine fibrinogen receptor antagonists from a constrained, RGD-containing cyclic semipeptide. The critical features incorporated into the design of these nonpeptides...
10.
Bhatnagar P, Huffman W, King A, Lovhaug D, Pelus L, Potts W, et al.
Pharm Biotechnol
. 1998 Oct;
11:367-91.
PMID: 9760688
No abstract available.